ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
AN2 Therapeutics Inc

AN2 Therapeutics Inc (ANTX)

1.04
0.00
(0.00%)
At close: 09 October 7:00AM
1.04
0.00
( 0.00% )
After Hours: 7:46AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.04
Bid
1.06
Offer
1.11
Volume
153,119
1.03 Day's Range 1.06
0.87 52 Week Range 22.22
Market Cap
Previous Close
1.04
Open
1.05
Last Trade
1063
@
1.04
Last Trade Time
07:00:00
Financial Volume
US$ 159,838
VWAP
1.0439
Average Volume (3m)
632,452
Shares Outstanding
29,842,431
Dividend Yield
-
PE Ratio
-0.48
Earnings Per Share (EPS)
-2.17
Revenue
-
Net Profit
-64.73M

About AN2 Therapeutics Inc

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
-
AN2 Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANTX. The last closing price for AN2 Therapeutics was US$1.04. Over the last year, AN2 Therapeutics shares have traded in a share price range of US$ 0.87 to US$ 22.22.

AN2 Therapeutics currently has 29,842,431 shares in issue. The market capitalisation of AN2 Therapeutics is US$31.04 million. AN2 Therapeutics has a price to earnings ratio (PE ratio) of -0.48.

ANTX Latest News

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today...

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today...

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Cash, cash equivalents, and investments of $104.5 million at June 30, 2024; cash runway anticipated to fund operations through 2027 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical...

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with MAC lung disease AN2 plans to shift focus to internal boron...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.02-1.886792452831.061.091.031173531.0535794CS
4-0.01-0.9523809523811.051.091.011852771.05311874CS
12-1.47-58.56573705182.513.070.876324521.1554423CS
26-2.06-66.45161290323.13.1850.873994941.51044179CS
52-13.62-92.905866302914.6622.220.873284103.63120858CS
156-15.81-93.827893175116.8523.580.871665435.42737872CS
260-15.81-93.827893175116.8523.580.871665435.42737872CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KXINKaixin Holdings
US$ 0.23
(27.78%)
1.61M
KZRKezar Life Sciences Inc
US$ 0.915
(23.65%)
3.75M
ICCTiCoreConnect Inc
US$ 0.41
(14.69%)
2.97M
ATXIAvenue Therapeutics Inc
US$ 2.20
(11.68%)
144
AQMSAqua Metals Inc
US$ 0.1594
(11.55%)
1.82k
HSDTHelius Medical Technologies Inc
US$ 0.4206
(-12.76%)
1.97k
CRDLCardiol Therapeutics Inc
US$ 1.73
(-11.73%)
148.96k
PIKKidpik Corporation
US$ 1.95
(-10.96%)
1.14k
NXLNexalin Technologies Inc
US$ 0.61
(-10.29%)
842.67k
SAGESage Therapeutics Inc
US$ 5.8001
(-9.80%)
2.03k
PBMPsyence Biomedical Ltd
US$ 0.115
(5.22%)
17.74M
GLUEMonte Rosa Therapeutics Inc
US$ 5.00
(0.00%)
5.71M
XPONExpion360 Inc
US$ 0.0299
(-0.66%)
4.75M
TIVCTivic Health Systems Inc
US$ 0.25
(-4.25%)
4.36M
KZRKezar Life Sciences Inc
US$ 0.915
(23.65%)
3.75M

ANTX Discussion

View Posts
Monksdream Monksdream 2 months ago
ANTX new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
ANTX under $3
πŸ‘οΈ0
eyeownu eyeownu 3 months ago
looking good
πŸ‘οΈ0
glenn1919 glenn1919 3 months ago
ANTX..............https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
GO4AWILDRIDE GO4AWILDRIDE 6 months ago
FROM 3/28 NEWS:

Cash, cash equivalents, and investments of $134.5 million at December 31, 2023

GO4AWILDRIDE
πŸ‘οΈ0
GO4AWILDRIDE GO4AWILDRIDE 6 months ago
THE FOLLOWING FROM THE 3/28 NEWS:

β€œAN2’s cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to believe in the potential of epetraborole to become an important component of the backbone therapy for NTM lung disease,” said Eric Easom, Co-Founder, President and Chief Executive Officer. β€œPatients enrolled in the epetraborole Phase 2/3 trial in treatment refractory lung disease caused by MAC continue to be dosed while new enrollment in the Phase 3 part of the trial remains paused. Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer. Analysis of the baseline patient demographics from the trial show a highly complex and refractory patient population, which we plan to discuss with the FDA in the coming months.”

GO4AWILDRIDE
πŸ‘οΈ0
GO4AWILDRIDE GO4AWILDRIDE 6 months ago
Monksdream

Did you read the 3/28 news from the compay?

Seems like the market is looking to chase the price up.

GLTU

GO4AWILDRIDE
πŸ‘οΈ0
GO4AWILDRIDE GO4AWILDRIDE 6 months ago
Monksdream

Seems like a nice rebound is starting to occur.

GLTU

GO4AWILDRIDE
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
ANTX new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
ANTX new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
ANTX new 52 week low
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock